---
schema_version: "secwatch.filing_event.v1"
accession: "0001479290-24-000099"
form_type: "8-K"
ticker: null
cik: "0001479290"
company_name: "Revance Therapeutics, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T05:31:23.683168+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Revance Q1 product revenue $51.7M (+13% YoY); launches Daxxify for cervical dystonia

## Summary
- Total net product revenue (DAXXIFY + RHA) $51.7M, up 13% YoY; DAXXIFY net $22.1M after $2M coupon.
- DAXXIFY aesthetic units sold +105% YoY; toxin market share 3.7% (up from 3.0% in Q4).
- Net loss from continuing ops $49.5M, comparable to $48.5M a year ago; cash $277.1M.
- FY 2024 guidance: total net product revenue at least $280M; funded to cash-flow breakeven in 2025.
- Launched DAXXIFY for cervical dystonia (CD), entering $2.7B U.S. therapeutic neurotoxin market; 78% commercial lives covered.

## SEC filing metadata
- accession: 0001479290-24-000099
- form_type: 8-K
- cik: 0001479290
- company_name: Revance Therapeutics, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479290/000147929024000099/0001479290-24-000099-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479290/000147929024000099/rvnc-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001479290-24-000099
- JSON: https://secwatch.observer/filing/0001479290-24-000099.json
- Plain text: https://secwatch.observer/filing/0001479290-24-000099.txt

## Key facts
- Earnings Releases
  Revance Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: reported results
  source text: Total net revenue for the first quarter ended March 31, 2024 was $51.9 million compared to $45.8 million for the same period last year, representing an increase of 13%, due to an increase in DAXXIFY sales volume.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1479290/000147929024000099/0001479290-24-000099-index.htm
- Earnings Releases
  Revance Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: reported results
  source text: Net loss from continuing operations for the first quarter ended March 31, 2024 was $49.5 million compared to $48.5 million for the same period in 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1479290/000147929024000099/0001479290-24-000099-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.